Axios Pro: Health Tech Deals

September 19, 2023

Axios Pro Exclusive Content

It's Tuesday, Health Tech enthusiasts.

πŸ—³οΈ Situational awareness: Hi! We'd like to learn more about you and your focus areas in your deals work. Please take 5 minutes to complete this survey.

1 big thing: Mural enrolls $8M for clinical trials tech

Illustration of a line of people waiting at a red cross-shaped door.

Illustration: Lindsey Bailey/Axios

Clinical trials facilitator Mural Health Technologies raised $8 million in seed funding, co-CEO Sam Whitaker tells Erin exclusively.

Why it matters: The clinical trials landscape is dominated by a few expensive and slow-moving studies run largely by elite, hard-to-access academic medical centers, and Mural hopes its payment and transport tech can help facilitate broader enrollment.

Details: Bessemer Venture Partners led the round and Bessemer partner Steve Kraus joined Mural's board of directors.

  • Virtue VC, Operator Partners, Arkitect Ventures, Correlation Ventures and Project Mayhem Ventures participated.
  • Funds will go towards expanding the company's sales and engineering teams and building out its transportation tools.
  • Whitaker envisions Mural raising a Series A in late 2024 or early 2025.

How it works: Mural's platform is designed to help clinical trial participants choose how they get paid for their contributions (whether that's PayPal, Venmo, ACH, check, or debit), get transportation to clinical sites through an Uber integration, and message with study personnel.

  • Mural is currently working with three pharmaceutical and biotech companies including Sonex Health (a developer of ultrasound-guided procedure technology) and is partnered with eClinical platforms including Clinical ink and Ledger Run.
  • The startup charges pharma companies fees to use its software on their clinical trials: "There is a clear link between making patients' lives easier and making money for the pharma company," Whitaker says.

Be smart: Clinical trials over-enroll affluent white patients and under-enroll others, curbing the relevance and applicability of research.

  • The FDA in February laid out a roadmap requiring any parties seeking clinical trial approval to outline plans to include more people of color.

The backstory: Before co-founding Mural with co-CEO Jason Dong, Whitaker started a clinical trial payments company called Greenphire β€” now Mural's primary competitor, in Whitaker's view.

What they're saying: Whitaker sees Mural's payment technology as both a continuation of his product work at Greenphire and a strategic touchpoint to influence other aspects of the clinical trials experience, such as diversifying participation by simplifying the process and collecting data on satisfaction.

  • "From a strategy perspective, we're evolving what was a point solution into a more strategic offering," he says. "We're really using payments to influence human behavior ... and coupling that with other features that make [participants'] lives easier."

One fun thing: Whitaker drew inspiration for Mural's name while looking at a mural in his office one day.

  • "A mural is a collection of many pieces of art that create a single entity. We think of clinical trials very similarly, in the sense that it's a large global effort made up of people from many different backgrounds and cultures," he says.

View archive